Gangtok Chronicle

CD BioSciences Offers a Full Range of Animal Model Customization Services for TME Research

 Breaking News
  • No posts were found

CD BioSciences Offers a Full Range of Animal Model Customization Services for TME Research

January 31
22:25 2023
CD BioSciences announced the release of its full range of animal model customization services to support TME research.

New York, USA – January 31, 2023 – TME center, the division of CD BioSciences, is an international biotechnology company focusing on research on the tumor microenvironment. With the continuous expansion of the company’s scale and the rave reviews of completed projects, CD BioSciences is committed to providing a full range of tumor research services to hospitals, research institutions and scientific researchers around the world, and promoting the process of new drug research. Recently, CD BioSciences announced the release of its full range of animal model customization services to support TME research.

The establishment of tumor animal models can evaluate the efficacy of anti-tumor immunotherapy. As a model for anti-tumor drug screening, it provides a powerful tool for the study of tumor occurrence and metastasis, allowing researchers to understand the mechanism of action of clinical drugs. With the deepening of tumor understanding and the development of experimental zoology, as well as the application of new technologies, the study of tumor animal models has made important progress.

CD BioSciences has established a mature tumor microenvironment center technology platform, has an experienced team of tumor model customization experts and mature technology, aiming to provide global customers with efficient and validated tumor models including existing models, custom models and new models developed composite services for tumor and microenvironment research as well as anticancer drug discovery.

CD BioSciences has established a variety of effective CDX models and can provide CDX models for breast cancer, liver cancer, intestinal cancer, pancreatic cancer, lung cancer, gastric cancer, kidney cancer, prostate cancer, melanoma, bladder cancer, leukemia, ovarian cancer and brain cancer, as well as the in vivo pharmacodynamics service of each model of the highly customized CDX model to assist in the research of targeted therapy in tumor and microenvironment.

CD BioSciences has also established a mature tumor microenvironment center technology platform, with a group of experienced tumor model customization experts and proven technologies, aiming to provide customers with efficient and verified tumor models for tumor and microenvironment research and anticancer drug discovery. In addition, CD BioSciences provides 3D cell model construction services, covering cell lines, substrates and consumables, culture medium systems, imaging analysis platforms and reagents, to help explore the relationship between tumor development and microenvironment.

“With extensive experience in various cancer models and expertise in tumors and the microenvironment, CD BioSciences is the ideal partner to support your cancer treatment research.” said Marcia Brady, the marketing director of CD BioSciences, she also claimed, “We provide customers with inventory model products, model customization, and joint research and development services to provide you with the best tumor models.”

About CD BioSciences

CD BioSciences provides global scientists and researchers with a full range of consulting, design, implementation, management, reporting and analysis services related to the study of the tumor microenvironment. CD BioSciences can help customers solve project problems or open up new research directions in all aspects to speed up research. In addition, we can also customize solutions for you according to your scientific research needs.

Media Contact
Company Name: CD BioSciences
Contact Person: Marcia Brady
Email: Send Email
Phone: 1-631-372-1052
Country: United States
Website: https://www.tmecenter.com

Recent Posts

Automotive Adhesives Market is Expected to Exceed US$ 9.3 Billion in Revenue by 2026| MarketsandMarkets™ Study

Read Full Article

Categories